https://orcid.org/0000-0003-2462-0581
Figures & data
Table 1 Patients and Disease Characteristics (n=45)
Table 2 Best Response of Pazopanib at 8 and 12 Weeks
Table 3 Pazopanib-Related Adverse Effects
Figure 1 Kaplan–Meier curves for progression-free survival and overall survival of pazopanib in soft tissue sarcoma.
Figure 2 Kaplan–Meier curves for progression-free survival based on ECOG PS (A), best response to pazopanib (B), and hypothyroidism (C).
Figure 3 Kaplan–Meier curves for overall survival based on hypothyroidism (A) and best response to pazopanib (B).
Figure 4 Kaplan–Meier curves for progression-free survival (A) and overall survival (B) of pazopanib based on histological subtypes of STS.
Table 4 Summary of Pazopanib in Real-World STS Data